Slide 1: 2007 Preliminary Results, Outlook for 2008
Milan, 7 February 2008 2007 Preliminary Results Outlook for 2008
Slide 2: 2007 Highlights
2007 Highlights ¾ Revenue € 628.4 million, up 9.1%, international sales grow by 14.0% ¾ EBIT € 131.5 million, up 9.3% ¾ Net income € 84.9 million, up 14.6% ¾ Acquisition of Orphan Europe for € 135 million ¾ Launch of Zanipress® (lercanidipine/enalapril fixed combination) in Germany ¾ Direct marketin
Slide 3: Composition of revenue
Composition of revenue (million Euro) 2007 2006 Change % Italy 201.3 200.5 0.4 France 140.5 134.0 4.8 Germany 52.8 51.3 2.9 Portugal 45.7 - n.s. Spain 21.9 30.5 (28.1) United Kingdom 11.6 10.7 8.5 Ireland 1.7 - n.s. Greece 0.8 - n.s. International licensees 118.2 110.8 6.7 TOTAL PHARMACEUTICALS 594.
Slide 4: Lercanidipine sales
Lercanidipine sales (million Euro) 2007 2006 Change % Italy 44.7 40.5 10.5 France 43.6 37.1 17.6 United Kingdom 11.3 10.6 6.4 Spain 7.5 8.5 (12.7) Germany 6.8 3.8 n.s. Others 5.3 1.5 n.s. DIRECT SALES 119.5 102.0 17.2 SALES TO LICENSEES 67.4 69.6 (3.2) TOTAL LERCANIDIPINE SALES 186.9 171.6 8.9 3
Slide 5: Full year 2007 results
Full year 2007 results (million Euro) 2007 2006 Change % Revenue 628.4 576.2 9.1 Gross Profit 422.1 384.2 9.9 as % of revenue 67.2% 66.7% SG&A Expenses 236.0 218.3 8.1 as % of revenue 37.6% 37.9% R&D Expenses 49.1 45.4 8.2 as % of revenue 7.8% 7.9% Other Income (Expense), net (5.5) (0.1) n.s. as % o
Slide 6: R&D pipeline
R&D pipeline NAME ORIGINATOR INDICATION DEVELOPMENT STATUS Launched in the RMS (Germany) Zanipress®/Zanitek® Recordati Hypertension (lercanidipine+enalapril) MRP ongoing rupatadine Uriach Rhinitis, allergic, seasonal / perennial urticaria Approved fentanyl patch Lavipharm Moderate to severe chronic
Slide 7: New lercanidipine combinations
New lercanidipine combinations ¾ To address new therapeutic guidelines for the treatment of hypertension and the increasing role of polytherapy, lercanidipine is being developed in fixed combinations with other broadly prescribed antihypertensive drugs ¾ One of the new combinations is based on lerca
Slide 8: Silodosin
Silodosin ¾ Selective alpha-1A receptor antagonist indicated for the symptomatic treatment of benign prostatic hyperplasia ¾ Benign prostatic hyperplasia increasing in frequency due to the progressive ageing of the population ¾ Originator: Kissei ¾ Market of reference: class G4C European sales, appr
Slide 9: New developments for Lower Urinary Tract Symptoms (LUTS) and incontinence
New developments for Lower Urinary Tract Symptoms (LUTS) and incontinence ¾ Irritative symptoms of the lower urinary tract (mainly urgency and frequency with or without incontinence) are frequent, mainly in women and the elderly. This condition, known as Overactive Bladder (OAB) is either idiopathic
Slide 10: R&D pipeline – drugs for rare diseases
R&D pipeline – drugs for rare diseases NAME ORIGINATOR INDICATION DEVELOPMENT STATUS Orphan Europe Approved in EU Carbaglu® NAGS deficiency Pre-registration in U.S. (Recordati) Orphan Europe Carbaglu® Organic acidemias Pre-registration in EU (Recordati) Orphan Europe Vitamin E deficiency in cystic f
Slide 11: Development of drugs for rare diseases
Development of drugs for rare diseases ¾ Carbaglu® (carglumic acid), a drug developed by Orphan Europe for the treatment of NAGS deficiency, approved in the EU in 2003, will be filed shortly for approval with the FDA. Carbaglu® is also in pre-registration phase in Europe for additional indications i
Slide 12: Development of drugs for rare diseases
Development of drugs for rare diseases ¾ Stanate® (stannsoporfin) Inhibits the production of bilirubin in cases of hyperbilirubinemia of different origin. Originated by Rockefeller University, is under development by InfaCare for the treatment of neonatal hyperbilirubinemia (jaundice). ¾ Severe hype
Slide 13: Development of drugs for rare diseases
Development of drugs for rare diseases ¾ Cystagon® (cysteamine bitartrate), a drug indicated for the treatment of nephropathic cystinosis, is being studied for a new and promising unrelated indication. ¾ Cystadrops® (cysteamine chlorhydrate), are eye drops developed for “ocular cystinosis” which can
Slide 14: Growth strategy
Growth strategy ¾ Achieve a direct presence in Eastern Europe ¾ Reinforce our R&D pipeline ¾ Growing strategic interest in specialized therapies: development of Stanate®, development of new drugs for rare diseases ¾ Reinforce our presence in Germany, Spain and the UK through selective company and/or
Slide 15: 2008 targets
2008 targets 2008 growth 2007 (million Euro) targets Revenue +10% 628.4 R&D expenses +20% 49.1 Operating income (EBIT) +10% 131.5 Net Income +14% 84.9 14
Slide 16: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finan